Advertisement

Topics

Eisai Inc Company Profile

00:06 EDT 20th June 2018 | BioPortfolio

Eisai is a human health care (hhc) company seeking innovative solutions in disease prevention, cure and care for the health and well-being of people worldwide. Our company's hhc mission symbol is derived from the letters in Florence Nightingale's signature. Following the example set by this famed health care pioneer, who devoted her life to caring for others yet never lost sight of the importance of listening to her patients, Eisai marshals its talents to explore new therapeutic approaches that address two key goals: meeting the medical needs of patients and their families, and improving their quality of life.

Location

Glenpointe Centre West500 Frank W. Burr Boulevard
Teaneck
New Jersey
07666
United States of America

Contact

Phone: 201-692-1100


News Articles [169 Associated News Articles listed on BioPortfolio]

BRIEF—Eisai completes oral solid dose production facility in China

Japanese pharma major Eisai says its Chinese subsidiary, Eisai China Inc (ECI) has completed construction…

UPDATE 1-Merck, Eisai sign deal to further develop, sell Eisai cancer drug

Merck & Co Inc and Japan's Eisai Co Ltd on Wednesday announced a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in d...

Merck, Eisai in deal to further develop, sell Eisai cancer drug

NEW YORK (Reuters) - Merck & Co Inc and Japan's Eisai Co Ltd on Wednesday announced a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already appr...

Merck, Eisai sign deal to further develop, sell Eisai cancer drug

(Reuters) - Merck & Co and Japan's Eisai Co Ltd on Wednesday announced a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in many ...

Eisai Plans Invests $100M in Genetics Guided Dementia Discovery Facility in Cambridge, Mass.

Eisai Inc. is adding to its arsenal aimed at combating dementia. The company will launch the Eisai Center for Genetics Guided Dementia Discovery.

Merck and Eisai co-develop Lenvima; expand combination trials

Merck & Co. Inc. and Eisai Co. Ltd. will co-develop and co-commercialize Eisai’s tyrosine kinase inhibitor Lenvima (lenvatinib) both as a monotherapy and in combination with Merck’s Keytruda (pemb...

Eisai: Launch of "Dementia Support" Insurance to Provide for Dementia in Japan

Jointly Developed by Eisai and Saint-PlusTOKYO, Feb 27, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced that it has jointly developed with Saint-Plus Small Amounts and Short Term Insurance Co., L...

Eisai clinches Merck deal to develop and sell cancer drug, shares soar

NEW YORK/TOKYO (Reuters) - Merck & Co Inc and Japan's Eisai Co Ltd have signed a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved ...

Drugs and Medications [11 Associated Drugs and Medications listed on BioPortfolio]

Halaven [Eisai Inc.]

These highlights do not include all the information needed to use HALAVEN™ safely and effectively. See full prescribing information for HALAVEN. HALAVEN™ (eribulin mesylate) Injection For intraven...

Lusedra [Eisai, Inc]

These highlights do not include all the information needed to use LUSEDRA safely and effectively. See full prescribing information for LUSEDRA. LUSEDRA (fospropofol disodium) Injection, for intravenou...

Ontak [Eisai, Inc]

These highlights do not include all the information needed to use Ontak safely and effectively. See full prescribing information for Ontak. ONTAK (denileukin diftitox) Injection for intravenous infusi...

Hexalen [Eisai Inc.]

HEXALEN (ALTRETAMINE) CAPSULES 50 mg R Only

Targretin [Eisai Inc.]

Targretin® (bexarotene) capsules, 75 mg

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Secondary patents in the pharmaceutical industry: Missing the wood for the trees?

Introduction The critics of the Innovator pharmaceutical industry allege that secondary patents are trivial modifications over the primary patent, which extend its term and delay the entry of the gene...

Clinical Trials [6 Associated Clinical Trials listed on BioPortfolio]

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Patients in Eisai Sponsored Lenvatinib Trials

This study will be conducted to assess the long-term safety of study drug(s) in participants who are enrolled in Eisai-sponsored lenvatinib studies.

A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)

This is a pilot trial to test perampanel (Fycompa; Eisai, Inc.) in ALS patients. The investigators will focus on safety and preliminary signs of efficacy. Perampanel is approved by the FDA...

Fasting Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Delayed-Release Tablets 20 mg

The objective of this study was to investigate the bioequivalence of Mylan's rabeprazole sodium delayed-release 20 mg tablets to Eisai's Aciphex® delayed-release 20 mg tablets following a...

PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment

On March 17th, 2011, the European Commission issued a marketing authorization valid throughout the European Union (EU) for Eribulin mesylate (Halaven; Eisai Limited), for the treatment of ...

Bioequivalence Study of Raperazole 20mg DR Tabs and PARIET® 20 mg DR Tabs Under Fed Conditions

This is an open-label, randomized, single dose, two-sequence, two-periods crossover study, separated by 7 days washout interval from the first Study Drug Administration. This study is cond...

Companies [14 Associated Companies listed on BioPortfolio]

Eisai GmbH

Auf dem globalen Pharmamarkt zählt Eisai zu den führenden forschungs- orientierten Pharmaunternehmen. Mit innovativen Präparaten für Erkrankungen des Zentralen Nerven- systems sowie im Magen-Darm-...

Eisai Europe Ltd

Eisai is committed to developing and delivering highly beneficial new treatments to help improve the lives of people with epilepsy. The development of AEDs is a major strategic ar...

Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Res...

Eisai Europe Limited

Eisai is committed to making further contributions to addressing the diversified needs and improving quality of life of patients with epilepsy. Eisai has three currently marketed treatments in Eur...

Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facili...

More Information about "Eisai Inc" on BioPortfolio

We have published hundreds of Eisai Inc news stories on BioPortfolio along with dozens of Eisai Inc Clinical Trials and PubMed Articles about Eisai Inc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Eisai Inc Companies in our database. You can also find out about relevant Eisai Inc Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Corporate Database Quicklinks



Searches Linking to this Company Record